6 recruiting, 5 unknown, 2 terminated, 1 completed. 8 Phase 2, 4 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Unknown 2, Completed 1, Not yet recruiting 1, Terminated 1 |
| Not applicable | 4 | Recruiting 2, Unknown 2 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Extrahepatic Cholangiocarcinoma: new trials by email Literature Review of Extrahepatic Cholangiocarcinoma trials Research Report on Extrahepatic Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-08-28 |
| Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma | Phase 2 / Phase 3 | Recruiting | Amsterdam UMC, location VUmc | 150 | 2026-04-17 | 2026-08-25 |
| Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide - Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 30 | 2026-03-02 | 2026-06-11 |
| Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma Endobiliary Radiofrequency Ablation (EB-RFA), Plastic Biliary Stent - Extrahepatic Cholangiocarcinoma | Not applicable | Recruiting | Aichi Medical University | 120 | 2025-11-20 | 2026-01-13 |
| Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma Gemcitabine, Cisplatin, Durvalumab - Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 42 | 2024-08-23 | 2026-10-23 |
| Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) Ablative local therapy - Small Bowel Cancer, Colorectal Cancer | Not applicable | Recruiting | University of California, Davis | 300 | 2023-10-05 | 2026-07-02 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma RFA, PDT, RFA combined with PDT - Extrahepatic Cholangiocarcinoma, Bile Duct Cancer | Not applicable | Unknown | First People's Hospital of Hangzhou | 70 | 2023-01-01 | 2023-02-21 |
| An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma Toripalimab, Gemcitabine,Oxaliplatin - Extrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Xuhua Duan | 45 | 2022-06-15 | 2022-07-07 |
| Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Irinotecan Liposome Injection, SG001, Fluorouracil - Advanced Biliary Tract Cancer, Intrahepatic Cholangiocarcinoma | Phase 2 | Terminated | CSPC Ouyi Pharmaceutical Co., Ltd. | 17 | 2021-09-01 | 2024-07-11 |
| Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma Spyglass + RFA, Cytobrush + RFA - Extrahepatic Cholangiocarcinoma, Malignant Biliary Obstruction | Not applicable | Unknown | First People's Hospital of Hangzhou | 200 | 2021-01-01 | 2023-08-15 |
| Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring - Biliary Tract Cancer, Cholangiocarcinoma | Terminated | University of Washington | 14 | 2020-07-08 | 2025-07-10 | |
| Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer Chemotherapy, Observation, Immunotherapy - Biliary Tract Cancer, Extrahepatic Cholangiocarcinoma | Phase 2 | Unknown | Sun Yat-sen University | 92 | 2020-06-01 | 2020-06-23 |
| A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma (Icc) | Recruiting | Yingbin Liu, MD, PhD, FACS | 1800 | 2020-01-01 | 2025-09-16 | |
| VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC) surgical treatment - Extrahepatic Cholangiocarcinoma | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 20 | 2006-07-01 | 2014-04-03 |
Cholangiocarcinoma (15) · Gallbladder Neoplasms (8) · Biliary Tract Neoplasms (6) · Klatskin Tumor (3) · Bile Duct Neoplasms (2) · Cirrhosis, Familial, with Pulmonary Hypertension (2) · Appendiceal Neoplasms (1) · Carcinoma (1) · Colorectal Neoplasms (1) · Disease (1) · Disease Progression (1) · Gastrointestinal Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1)
Adenocarcinoma (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms, Glandular and Epithelial (15) · Carcinoma (14) · Biliary Tract Diseases (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Neoplasms by Site (10) · Gallbladder Diseases (8) · Biliary Tract Neoplasms (4) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bile Duct Diseases (2) · Gastrointestinal Diseases (2)
Gemcitabine (4) · Cisplatin (3) · Fluorouracil (2) · Leucovorin (2) · Oxaliplatin (2) · durvalumab (2) · 1-phenyl-3,3-dimethyltriazene (1) · Cyclophosphamide (1) · Drug Therapy (1) · Folfox protocol (1) · Immunotherapy (1) · Observation (1) · Radiofrequency Ablation (1) · Radiotherapy (1) · Surgical Procedures, Operative (1)
First People's Hospital of Hangzhou (2) · Aichi Medical University (1) · Amsterdam UMC, location VUmc (1) · Beijing Biotech (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Lisata Therapeutics, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Sun Yat-sen University (1) · University of California, Davis (1) · University of Washington (1) · Xuhua Duan (1) · Yingbin Liu, MD, PhD, FACS (1)
China (8) · United States (4) · Germany (1) · Japan (1) · Netherlands (1) · South Korea (1)
Edward Kim, MD, PhD (1) · Gentry King, MD (1) · Jae Hee Cho, Professor (1) · Jianfeng Yang (1) · Kristen K Buck, MD (1) · Ming Kuang, MD (1) · Ming Kuang, PhD (1) · Nilo Azad, MD (1) · Salah-Eddin SE Al-Batran, Prof. Dr. (1) · Tadahisa Inoue, Associate Professor (1) · Xiangdong Cheng (1) · Xiaofeng Zhang (1) · Yingbin Liu, PhD (1)
PMID 29342492, PMID 33104917, PMID 33259690, PMID 34995788, PMID 36372281, PMID 38477985, PMID 40068597, PMID 40638104
2023 (2), P30CA093373 (1)